ClinicalTrials.gg
CompletedNCT02738333Updated Nov 16, 2018Results posted

Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Participants With Chronic Genotype 2 HCV Infection

A Phase 3 interventional study of LDV/SOF and SOF in Hepatitis C Virus Infection, sponsored by Gilead Sciences. Completed at 37 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2018-11-16.

Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
239
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 94 studies testing sofosbuvir in Hepatitis C — 1 open to participants now, 3 under way, none of them phase 3. Sofosbuvir · Hepatitis C.

Enrollment
18th of 94
239 · median 75
Started
2016
with 12 others
Phase 3
30 of 94
none open now
Registered
52nd of 94
by date
Lead sponsor
30 of 94
Gilead Sciences

Among the 94 studies testing sofosbuvir in Hepatitis C, this one is the 18th largest by enrollment, is one of 13 that started in 2016, is one of 30 in phase 3, and was the 52nd registered.

Hepatitis C

1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.

Browse Hepatitis C studies →

Open to participants now

1 of the 94 studies testing sofosbuvir in Hepatitis C is open now. Recruiting first, the newest first:

About sofosbuvir

Sofosbuvir: first FDA approval 2013 (SOVALDI), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 94 studies testing sofosbuvir in Hepatitis C, or all of them as a file.
02

Study summary

The primary objectives of this study are to evaluate the antiviral efficacy of therapy with ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) and to evaluate the safety and tolerability of LDV/SOF FDC and sofosbuvir (SOF) + ribavirin (RBV) in participants with chronic genotype 2 hepatitis C virus (HCV) infection.

03

Conditions studied

  • Hepatitis C Virus Infection

Browse trials for

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Chronic genotype 2 -infected males and non-pregnant/non-lactating females
  • Aged 20 years or older
  • Treatment naive or treatment experienced
  • At least 20 subjects will have -A compensated cirrhosis. In Cohort 2, participants must be ineligible or intolerant of RBV.

Key Exclusion Criteria:

  • Previous exposure to an NS5A or NS5B inhibitor
  • Infection with virus (HBV) or (HIV)
  • Pregnant or nursing female or male with pregnant female partner

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
239 participants (actual)

Study arms

  • Experimental
    LDV/SOF (Cohort 1)

    LDV/SOF FDC for 12 weeks

    Drug: LDV/SOF

  • Experimental
    SOF+RBV (Cohort 1)

    SOF+RBV for 12 weeks

    Drug: SOF · Drug: RBV

  • Experimental
    LDV/SOF (Cohort 2)

    Participants who are ineligible for or intolerant to RBV therapy will receive LDV/SOF FDC for 12 weeks.

    Drug: LDV/SOF

Interventions

  • DrugLDV/SOF

    90/400 mg FDC tablet administered orally once daily

    Also known as: Harvoni®, GS-5885/GS-7977

  • DrugSOF

    400 mg tablet administered orally once daily

    Also known as: Sovaldi®, GS-7977, PSI-7977

  • DrugRBV

    Capsules administered orally in a divided daily dose according to package insert weight-based dosing recommendations (≤ 60 kg = 600 mg, \> 60 kg to ≤ 80 kg = 800 mg, and \> 80 kg = 1000 mg)

    Also known as: REBETOL®

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)

    SVR12 was defined as HCV RNA \< the lower limit of quantitation (LLOQ; ie, 15 IU/mL) at 12 weeks after stopping study treatment.

    Time frame: Posttreatment Week 12

  2. Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event

    Time frame: Up to 12 weeks

Secondary outcomes

  1. Percentage of Participants With SVR at 4 Weeks After Discontinuation of Therapy (SVR4)

    SVR4 was defined as HCV RNA \< LLOQ at 4 weeks after stopping study treatment.

    Time frame: Posttreatment Week 4

  2. Percentage of Participants With SVR at 24 Weeks After Discontinuation of Therapy (SVR24)

    SVR 24 was defined as HCV RNA \< LLOQ at 24 weeks after stopping study treatment.

    Time frame: Posttreatment Week 24

  3. Percentage of Participants With HCV RNA < LLOQ at Week 1

    Time frame: Week 1

  4. Percentage of Participants With HCV RNA < LLOQ at Week 2

    Time frame: Week 2

  5. Percentage of Participants With HCV RNA < LLOQ at Week 3

    Time frame: Week 3

  6. Percentage of Participants With HCV RNA < LLOQ at Week 4

    Time frame: Week 4

  7. Percentage of Participants With HCV RNA < LLOQ at Week 5

    Time frame: Week 5

  8. Percentage of Participants With HCV RNA < LLOQ at Week 6

    Time frame: Week 6

  9. Percentage of Participants With HCV RNA < LLOQ at Week 8

    Time frame: Week 8

  10. Percentage of Participants With HCV RNA < LLOQ at Week 10

    Time frame: Week 10

  11. Percentage of Participants With HCV RNA < LLOQ at Week 12

    Time frame: Week 12

  12. Change From Baseline in HCV RNA at Week 1

    Time frame: Baseline; Week 1

  13. Change From Baseline in HCV RNA at Week 2

    Time frame: Baseline; Week 2

  14. Change From Baseline in HCV RNA at Week 3

    Time frame: Baseline; Week 3

  15. Change From Baseline in HCV RNA at Week 4

    Time frame: Baseline; Week 4

  16. Change From Baseline in HCV RNA at Week 5

    Time frame: Baseline; Week 5

  17. Change From Baseline in HCV RNA at Week 6

    Time frame: Baseline; Week 6

  18. Change From Baseline in HCV RNA at Week 8

    Time frame: Baseline; Week 8

  19. Change From Baseline in HCV RNA at Week 10

    Time frame: Baseline; Week 10

  20. Change From Baseline in HCV RNA at Week 12

    Time frame: Baseline; Week 12

  21. Percentage of Participants With Overall Virologic Failure

    Virologic failure was defined as: * On-treatment virologic failure: * Breakthrough (confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA \< LLOQ while on treatment), or * Rebound (confirmed \> 1 log10 IU/mL increase in HCV RNA from nadir while on treatment), or * Non-response (HCV RNA persistently ≥ LLOQ through 8 weeks of treatment) * Virologic relapse: * Confirmed HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA \< LLOQ at last on-treatment visit.

    Time frame: Up to Posttreatment Week 24

07

Results

Posted Mar 14, 2018

Participant flow

Participants were enrolled at study sites in Japan. The first participant was screened on 12 April 2016. The last study visit occurred on 11 May 2017.

Participant flow — Overall Study
MilestoneLDV/SOF (Cohort 1)SOF+RBV (Cohort 1)LDV/SOF (Cohort 2)
Started10610825
Completed10410825
Not completed200
Withdrew: Death100
Withdrew: Lost to follow-up100

Outcome measures

PrimaryPercentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)

SVR12 was defined as HCV RNA \< the lower limit of quantitation (LLOQ; ie, 15 IU/mL) at 12 weeks after stopping study treatment.

Time frame:
Posttreatment Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)
percentage of participantsLDV/SOF (Cohort 1)SOF+RBV (Cohort 1)LDV/SOF (Cohort 2)
Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)96.2 (90.6 to 99.0)95.4 (89.5 to 98.5)96.0 (79.6 to 99.9)
Statistical analysis
  • LDV/SOF (Cohort 1) vs SOF+RBV (Cohort 1) · Difference in proportions: 0.9 · 95% CI -5.3 to 7.1Difference in proportions between treatment groups and associated 95% confidence intervals (CI) are calculated based on stratum-adjusted Mantel-Haenszel proportions.
PrimaryPercentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event
Time frame:
Up to 12 weeks
Reported as:
Number · percentage of participants
Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event
percentage of participantsLDV/SOF (Cohort 1)SOF+RBV (Cohort 1)LDV/SOF (Cohort 2)
Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event0.91.90
SecondaryPercentage of Participants With SVR at 4 Weeks After Discontinuation of Therapy (SVR4)

SVR4 was defined as HCV RNA \< LLOQ at 4 weeks after stopping study treatment.

Time frame:
Posttreatment Week 4
Reported as:
Number · percentage of participants
Percentage of Participants With SVR at 4 Weeks After Discontinuation of Therapy (SVR4)
percentage of participantsLDV/SOF (Cohort 1)SOF+RBV (Cohort 1)LDV/SOF (Cohort 2)
Percentage of Participants With SVR at 4 Weeks After Discontinuation of Therapy (SVR4)97.2 (92.0 to 99.4)98.1 (93.5 to 99.8)96.0 (79.6 to 99.9)
SecondaryPercentage of Participants With SVR at 24 Weeks After Discontinuation of Therapy (SVR24)

SVR 24 was defined as HCV RNA \< LLOQ at 24 weeks after stopping study treatment.

Time frame:
Posttreatment Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With SVR at 24 Weeks After Discontinuation of Therapy (SVR24)
percentage of participantsLDV/SOF (Cohort 1)SOF+RBV (Cohort 1)LDV/SOF (Cohort 2)
Percentage of Participants With SVR at 24 Weeks After Discontinuation of Therapy (SVR24)96.2 (90.6 to 99.0)95.4 (89.5 to 98.5)96.0 (79.6 to 99.9)
SecondaryPercentage of Participants With HCV RNA < LLOQ at Week 1
Time frame:
Week 1
Reported as:
Number · percentage of participants
Percentage of Participants With HCV RNA < LLOQ at Week 1
percentage of participantsLDV/SOF (Cohort 1)SOF+RBV (Cohort 1)LDV/SOF (Cohort 2)
Percentage of Participants With HCV RNA < LLOQ at Week 124.5 (16.7 to 33.8)31.5 (22.9 to 41.1)32.0 (14.9 to 53.5)
SecondaryPercentage of Participants With HCV RNA < LLOQ at Week 2
Time frame:
Week 2
Reported as:
Number · percentage of participants
Percentage of Participants With HCV RNA < LLOQ at Week 2
percentage of participantsLDV/SOF (Cohort 1)SOF+RBV (Cohort 1)LDV/SOF (Cohort 2)
Percentage of Participants With HCV RNA < LLOQ at Week 273.6 (64.1 to 81.7)76.6 (67.5 to 84.3)76.0 (54.9 to 90.6)
SecondaryPercentage of Participants With HCV RNA < LLOQ at Week 3
Time frame:
Week 3
Reported as:
Number · percentage of participants
Percentage of Participants With HCV RNA < LLOQ at Week 3
percentage of participantsLDV/SOF (Cohort 1)SOF+RBV (Cohort 1)LDV/SOF (Cohort 2)
Percentage of Participants With HCV RNA < LLOQ at Week 390.6 (83.3 to 95.4)90.7 (83.5 to 95.4)96.0 (79.6 to 99.9)
SecondaryPercentage of Participants With HCV RNA < LLOQ at Week 4
Time frame:
Week 4
Reported as:
Number · percentage of participants
Percentage of Participants With HCV RNA < LLOQ at Week 4
percentage of participantsLDV/SOF (Cohort 1)SOF+RBV (Cohort 1)LDV/SOF (Cohort 2)
Percentage of Participants With HCV RNA < LLOQ at Week 498.1 (93.4 to 99.8)96.3 (90.7 to 99.0)100.0 (86.3 to 100.0)
SecondaryPercentage of Participants With HCV RNA < LLOQ at Week 5
Time frame:
Week 5
Reported as:
Number · percentage of participants
Percentage of Participants With HCV RNA < LLOQ at Week 5
percentage of participantsLDV/SOF (Cohort 1)SOF+RBV (Cohort 1)LDV/SOF (Cohort 2)
Percentage of Participants With HCV RNA < LLOQ at Week 598.1 (93.3 to 99.8)99.1 (94.9 to 100.0)100.0 (86.3 to 100.0)
SecondaryPercentage of Participants With HCV RNA < LLOQ at Week 6
Time frame:
Week 6
Reported as:
Number · percentage of participants
Percentage of Participants With HCV RNA < LLOQ at Week 6
percentage of participantsLDV/SOF (Cohort 1)SOF+RBV (Cohort 1)LDV/SOF (Cohort 2)
Percentage of Participants With HCV RNA < LLOQ at Week 699.0 (94.8 to 100.0)99.1 (94.9 to 100.0)100.0 (86.3 to 100.0)
SecondaryPercentage of Participants With HCV RNA < LLOQ at Week 8
Time frame:
Week 8
Reported as:
Number · percentage of participants
Percentage of Participants With HCV RNA < LLOQ at Week 8
percentage of participantsLDV/SOF (Cohort 1)SOF+RBV (Cohort 1)LDV/SOF (Cohort 2)
Percentage of Participants With HCV RNA < LLOQ at Week 8100.0 (96.5 to 100.0)100.0 (96.6 to 100.0)100.0 (86.3 to 100.0)
SecondaryPercentage of Participants With HCV RNA < LLOQ at Week 10
Time frame:
Week 10
Reported as:
Number · percentage of participants
Percentage of Participants With HCV RNA < LLOQ at Week 10
percentage of participantsLDV/SOF (Cohort 1)SOF+RBV (Cohort 1)LDV/SOF (Cohort 2)
Percentage of Participants With HCV RNA < LLOQ at Week 10100.0 (96.5 to 100.0)100.0 (96.6 to 100.0)100.0 (86.3 to 100.0)
SecondaryPercentage of Participants With HCV RNA < LLOQ at Week 12
Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With HCV RNA < LLOQ at Week 12
percentage of participantsLDV/SOF (Cohort 1)SOF+RBV (Cohort 1)LDV/SOF (Cohort 2)
Percentage of Participants With HCV RNA < LLOQ at Week 12100.0 (96.5 to 100.0)100.0 (96.6 to 100.0)100.0 (86.3 to 100.0)
SecondaryChange From Baseline in HCV RNA at Week 1
Time frame:
Baseline; Week 1
Reported as:
Mean · log10 IU/mL
Change From Baseline in HCV RNA at Week 1
log10 IU/mLLDV/SOF (Cohort 1)SOF+RBV (Cohort 1)LDV/SOF (Cohort 2)
Change From Baseline in HCV RNA at Week 1-4.18 ± 0.540-4.34 ± 0.602-4.24 ± 0.550
SecondaryChange From Baseline in HCV RNA at Week 2
Time frame:
Baseline; Week 2
Reported as:
Mean · log10 IU/mL
Change From Baseline in HCV RNA at Week 2
log10 IU/mLLDV/SOF (Cohort 1)SOF+RBV (Cohort 1)LDV/SOF (Cohort 2)
Change From Baseline in HCV RNA at Week 2-4.76 ± 0.759-4.81 ± 0.772-4.64 ± 0.719
SecondaryChange From Baseline in HCV RNA at Week 3
Time frame:
Baseline; Week 3
Reported as:
Mean · log10 IU/mL
Change From Baseline in HCV RNA at Week 3
log10 IU/mLLDV/SOF (Cohort 1)SOF+RBV (Cohort 1)LDV/SOF (Cohort 2)
Change From Baseline in HCV RNA at Week 3-4.87 ± 0.780-4.89 ± 0.790-4.75 ± 0.714
SecondaryChange From Baseline in HCV RNA at Week 4
Time frame:
Baseline; Week 4
Reported as:
Mean · log10 IU/mL
Change From Baseline in HCV RNA at Week 4
log10 IU/mLLDV/SOF (Cohort 1)SOF+RBV (Cohort 1)LDV/SOF (Cohort 2)
Change From Baseline in HCV RNA at Week 4-4.89 ± 0.782-4.91 ± 0.794-4.76 ± 0.719
SecondaryChange From Baseline in HCV RNA at Week 5
Time frame:
Baseline; Week 5
Reported as:
Mean · log10 IU/mL
Change From Baseline in HCV RNA at Week 5
log10 IU/mLLDV/SOF (Cohort 1)SOF+RBV (Cohort 1)LDV/SOF (Cohort 2)
Change From Baseline in HCV RNA at Week 5-4.91 ± 0.781-4.92 ± 0.794-4.76 ± 0.719
SecondaryChange From Baseline in HCV RNA at Week 6
Time frame:
Baseline; Week 6
Reported as:
Mean · log10 IU/mL
Change From Baseline in HCV RNA at Week 6
log10 IU/mLLDV/SOF (Cohort 1)SOF+RBV (Cohort 1)LDV/SOF (Cohort 2)
Change From Baseline in HCV RNA at Week 6-4.91 ± 0.781-4.92 ± 0.793-4.76 ± 0.719
SecondaryChange From Baseline in HCV RNA at Week 8
Time frame:
Baseline; Week 8
Reported as:
Mean · log10 IU/mL
Change From Baseline in HCV RNA at Week 8
log10 IU/mLLDV/SOF (Cohort 1)SOF+RBV (Cohort 1)LDV/SOF (Cohort 2)
Change From Baseline in HCV RNA at Week 8-4.92 ± 0.785-4.93 ± 0.794-4.76 ± 0.719
SecondaryChange From Baseline in HCV RNA at Week 10
Time frame:
Baseline; Week 10
Reported as:
Mean · log10 IU/mL
Change From Baseline in HCV RNA at Week 10
log10 IU/mLLDV/SOF (Cohort 1)SOF+RBV (Cohort 1)LDV/SOF (Cohort 2)
Change From Baseline in HCV RNA at Week 10-4.92 ± 0.785-4.93 ± 0.794-4.76 ± 0.719
SecondaryChange From Baseline in HCV RNA at Week 12
Time frame:
Baseline; Week 12
Reported as:
Mean · log10 IU/mL
Change From Baseline in HCV RNA at Week 12
log10 IU/mLLDV/SOF (Cohort 1)SOF+RBV (Cohort 1)LDV/SOF (Cohort 2)
Change From Baseline in HCV RNA at Week 12-4.92 ± 0.785-4.92 ± 0.794-4.76 ± 0.719
SecondaryPercentage of Participants With Overall Virologic Failure

Virologic failure was defined as: * On-treatment virologic failure: * Breakthrough (confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA \< LLOQ while on treatment), or * Rebound (confirmed \> 1 log10 IU/mL increase in HCV RNA from nadir while on treatment), or * Non-response (HCV RNA persistently ≥ LLOQ through 8 weeks of treatment) * Virologic relapse: * Confirmed HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA \< LLOQ at last on-treatment visit.

Time frame:
Up to Posttreatment Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Overall Virologic Failure
percentage of participantsLDV/SOF (Cohort 1)SOF+RBV (Cohort 1)LDV/SOF (Cohort 2)
Percentage of Participants With Overall Virologic Failure2.83.74.0

Adverse events

Collected over Up to 12 weeks plus 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LDV/SOF (Cohort 1)1/106 (0.9%)1/106 (0.9%)25/106 (23.6%)
SOF+RBV (Cohort 1)0/108 (0%)1/108 (0.9%)48/108 (44.4%)
LDV/SOF (Cohort 2)0/25 (0%)1/25 (4%)7/25 (28%)
Most frequent serious events
Most frequent serious events
EventLDV/SOF (Cohort 1)SOF+RBV (Cohort 1)LDV/SOF (Cohort 2)
Cerebral infarctionNervous system disorders0/1060/1081/25
Mallory-Weiss syndromeGastrointestinal disorders1/1060/1080/25
Hip fractureInjury, poisoning and procedural complications0/1061/1080/25
Most frequent other events
Most frequent other events
EventLDV/SOF (Cohort 1)SOF+RBV (Cohort 1)LDV/SOF (Cohort 2)
AnaemiaBlood and lymphatic system disorders0/10625/1080/25
Viral upper respiratory tract infectionInfections and infestations12/10623/1081/25
HeadacheNervous system disorders10/1069/1082/25
StomatitisGastrointestinal disorders4/1062/1082/25
PyrexiaGeneral disorders0/1060/1082/25

Baseline characteristics

Safety Analysis Set: participants who took at least 1 dose of study drug

Age, Continuous
Age, Continuous(years)LDV/SOF (Cohort 1)SOF+RBV (Cohort 1)LDV/SOF (Cohort 2)Total
Mean58 ± 10.560 ± 12.374 ± 7.161 ± 11.9
Sex: Female, Male
Sex: Female, Male(Participants)LDV/SOF (Cohort 1)SOF+RBV (Cohort 1)LDV/SOF (Cohort 2)Total
Female547119144
Male5237695
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)LDV/SOF (Cohort 1)SOF+RBV (Cohort 1)LDV/SOF (Cohort 2)Total
Hispanic or Latino0000
Not Hispanic or Latino10610825239
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)LDV/SOF (Cohort 1)SOF+RBV (Cohort 1)LDV/SOF (Cohort 2)Total
American Indian or Alaska Native0000
Asian10610825239
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White0000
More than one race0000
Unknown or Not Reported0000
IL28b Status
IL28b Status(Participants)LDV/SOF (Cohort 1)SOF+RBV (Cohort 1)LDV/SOF (Cohort 2)Total
CC888615189
CT17191046
TT1304
HCV RNA (log10 IU/mL)
HCV RNA (log10 IU/mL)(log10 IU/mL)LDV/SOF (Cohort 1)SOF+RBV (Cohort 1)LDV/SOF (Cohort 2)Total
Mean6.1 ± 0.796.1 ± 0.795.9 ± 0.726.0 ± 0.78
HCV RNA Category
HCV RNA Category(Participants)LDV/SOF (Cohort 1)SOF+RBV (Cohort 1)LDV/SOF (Cohort 2)Total
< 800,000 IU/mL30361076
≥ 800,000 IU/mL767215163
08

Study locations

37 sites
  • Bunkyo, Japan
  • Chiba, Japan
  • Chuo City, Japan
  • Ehime, Japan
  • Fukuoka, Japan
  • Fukuyama, Japan
  • Gifu, Japan
  • Ibaragi, Japan
  • Ikeda, Japan
  • Iruma-gun, Japan
  • Itabashi, Japan
  • Izunokuni, Japan
  • Kagoshima, Japan
  • Kashihara, Japan
  • Kitakyushu, Japan
  • Kumamoto, Japan
  • Kyoto, Japan
  • Maebashi, Japan
  • Matsumoto, Japan
  • Morioka, Japan
  • Musashino, Japan
  • Nagasaki, Japan
  • Nagoya, Japan
  • Nishinomiya, Japan
  • Ogaki City, Japan
  • Okayama, Japan
  • Omura, Japan
  • Osaka, Japan
  • Sagamihara, Japan
  • Saga, Japan
  • Sapporo, Japan
  • Sendai, Japan
  • Suita, Japan
  • Takamatsu, Japan
  • Ube, Japan
  • Yamagata, Japan
  • Yufu, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.

Supporting information: Study protocol, Statistical analysis plan

Time frame: 18 months after study completion

Access criteria: A secured external environment with username, password, and RSA code.

Data sharing details ↗ · www.gilead.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2016 to primary completion in Feb 2017, 10 months.

Results were first posted in Mar 2018, 1 year 1 month after primary completion.

Of 68 industry-sponsored phase 3 interventional studies under Hepatitis C, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 18. This study's 10 months is below that.

Counting every sponsor, half of 90 studies reached it within 14 months; a quarter within 10 and three quarters within 22.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 11, 2016
First posted
Apr 14, 2016
StartActual
Apr 12, 2016
Primary completionActual
Feb 14, 2017
CompletionActual
May 11, 2017
Results first posted
Mar 14, 2018
Last update
Nov 16, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 16, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02738333
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Apr 14, 2016
Start date
Apr 12, 2016
Primary completion
Feb 14, 2017
Completion
May 11, 2017
Results posted
Mar 14, 2018
Last update
Nov 16, 2018

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sofosbuvir · Ribavirin

Start the discussion